Clinical Trial Update: Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and tolerability of a single oral dose of CNDO-201 Trichuris suis ova in Crohn's disease patients. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CNDO-201 (Trichuris suis ova)

Snippet

Sponsor: Coronado Biosciences, Inc. | Conditions: Crohn's Disease | Phase 1 | Status: COMPLETED | Results posted: 2013-05-20